VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Viridian Therapeutics, Inc.\DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$20.80+1.77 (+9.30%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
136M of 113M shares
Institutional holders
214
47 new, 55 sold out
Net institutional buying
24M
In Q2 2026
Insider trades, 12 months
2 buys · 3 sales
Net bought $29.58M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC | 7,625,542 | 14.50% | 13G (passive) | Jan 10, 2024 |
| Bellevue Group AG | 6,726,144 | 6.60% | 13G (passive) | Mar 31, 2026 |
| Senai Asefaw, M.D. | 6,723,788 | 6.10% | 13G (passive) amendment | Jun 30, 2026 |
| State Street Corporation | 6,124,976 | 5.50% | 13G (passive) | Jun 30, 2026 |
| T. Rowe Price Associates, Inc. | 5,748,426 | 5.20% | 13G (passive) | Jun 30, 2026 |
| Point72 Asset Management, L.P. | 5,687,507 | 5.00% | 13G (passive) | Aug 19, 2026 |
| David Kroin | 5,417,660 | 5.30% | 13G (passive) | May 1, 2026 |
| BlackRock, Inc. | 3,426,450 | 6.50% | 13G (passive) amendment | Dec 31, 2023 |
| Fairmount Funds Management LLC | 17,201,800 | 14.04% | 13D (active) amendment | May 11, 2026 |
| Fairmount Healthcare Fund II GP LLC | 16,025,330 | 15.14% | 13D (active) amendment | Oct 23, 2025 |
| Kynam Capital Management GP, LLC | 0 | 5.70% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VRDN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 16,604,740 | 14.66% | $305.03M | +1,225,363 | 0.01% |
| BlackRock, Inc. | 8,551,488 | 7.55% | $157.09M | +720,013 | 0.00% |
| Bellevue Group AG | 6,731,909 | 5.94% | $123.67M | +5,765 | 2.60% |
| Paradigm Biocapital Advisors LP | 6,723,788 | 5.93% | $123.52M | +3,574,895 | 2.31% |
| Kynam Capital Management, LP | 6,453,877 | 5.70% | $118.56M | +4,112,225 | 6.55% |
| State Street Corp | 6,124,976 | 5.41% | $112.52M | +1,452,091 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 5,748,410 | 5.07% | $105.60K | +2,542,375 | 0.01% |
| Fairmount Funds Management LLC | 5,090,928 | 4.49% | $93.52M | +1,176,470 | 6.18% |
| Vanguard Capital Management LLC | 4,576,860 | 4.04% | $84.08M | +409,659 | 0.00% |
| Deep Track Capital, LP | 3,592,740 | 3.17% | $66.00M | +2,198,796 | 0.96% |
| VR Adviser, LLC | 3,257,917 | 2.88% | $59.85M | −624,792 | 1.81% |
| Wellington Management Group Llp | 3,128,362 | 2.76% | $57.47M | +49,808 | 0.01% |
| Vanguard Portfolio Management LLC | 2,752,827 | 2.43% | $50.57M | +1,111,350 | 0.00% |
| Geode Capital Management, LLC | 2,501,869 | 2.21% | $45.97M | +168,656 | 0.00% |
| Avoro Capital Advisors LLC | 2,500,000 | 2.21% | $45.93M | +1,000,000 | 0.41% |
| Baker Bros. Advisors LP | 2,383,025 | 2.10% | $43.78M | +411,347 | 0.22% |
| Point72 Asset Management, L.P. | 2,343,208 | 2.07% | $43.04M | +2,020,372 | 0.05% |
| Caligan Partners LP | 2,193,981 | 1.94% | $40.30M | New | 1.90% |
| Novo Holdings A/S | 2,135,000 | 1.88% | $39.22M | +135,000 | 2.28% |
| Tang Capital Management LLC | 1,792,626 | 1.58% | $32.93M | – | 1.50% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 214 | 136M | 100.0% | 47 / 96 | 50 / 55 | 39M | 16M |
| Q1 2026 | 225 | 112M | 99.2% | 49 / 80 | 67 / 50 | 28M | 17M |
| Q4 2025 | 229 | 108M | 95.2% | 77 / 85 | 45 / 15 | 32M | 18M |
| Q3 2025 | 169 | 94M | 82.5% | 17 / 53 | 65 / 18 | 5M | 7M |
| Q2 2025 | 170 | 95M | 83.8% | 22 / 61 | 65 / 28 | 10M | 7M |
| Q1 2025 | 176 | 91M | 80.7% | 26 / 68 | 54 / 27 | 10M | 9M |
| Q4 2024 | 178 | 91M | 80.4% | 42 / 79 | 42 / 24 | 15M | 11M |
| Q3 2024 | 165 | 88M | 77.3% | 45 / 65 | 41 / 16 | 29M | 7M |
| Q2 2024 | 138 | 70M | 61.6% | 20 / 70 | 28 / 16 | 11M | 13M |
| Q1 2024 | 136 | 72M | 64.0% | 23 / 64 | 34 / 19 | 17M | 5M |
| Q4 2023 | 132 | 61M | 53.6% | 25 / 49 | 43 / 16 | 21M | 10M |
| Q3 2023 | 123 | 50M | 44.3% | 14 / 55 | 36 / 18 | 8M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of VRDN | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,923,620 | 3.46% | $72.08M | 0.67% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,336,970 | 2.95% | $61.30M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,348,604 | 2.07% | $43.14M | 0.05% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 1,782,464 | 1.57% | $33.72M | 1.53% | Jul 31, 2026 |
| Select Health Care Portfolio | 1,500,000 | 1.32% | $26.43M | 0.46% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,447,742 | 1.28% | $26.60M | 0.22% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,386,319 | 1.22% | $24.43M | 0.01% | May 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,351,696 | 1.19% | $24.83M | 0.17% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,308,304 | 1.15% | $23.05M | 0.44% | May 31, 2026 |
| Fidelity Small Cap Growth Fund | 1,268,990 | 1.12% | $24.01M | 0.27% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,130,424 | 1.00% | $20.77M | 0.02% | Jun 30, 2026 |
| Fidelity Stock Selector Small Cap Fund | 1,089,196 | 0.96% | $20.61M | 0.28% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 987,199 | 0.87% | $18.68M | 0.05% | Jul 31, 2026 |
| Vanguard Explorer Fund | 960,500 | 0.85% | $18.17M | 0.08% | Jul 31, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 791,842 | 0.70% | $14.98M | 0.32% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Stephen F. Mahoney | President and CEO, Director | 33,349 | 0.03% | Mar 9, 2026 |
| Jennifer Tousignant | Chief Legal Officer | 0 | – | Aug 20, 2026 |
| Radhika Tripuraneni | Chief Medical Officer | 40,000 | 0.04% | Aug 18, 2026 |
| Seth Harmon | Chief Financial Officer | 7,850 | 0.01% | Mar 9, 2026 |
| Thomas W. Beetham | Chief Operating Officer | 13,361 | 0.01% | Mar 9, 2026 |
| Jennifer K. Moses | Director | – | – | Jul 2, 2026 |
| Sarah Gheuens | Director | – | – | Jul 2, 2026 |
| Jeffrey Robert Ajer | Director | – | – | Jul 2, 2026 |
| Tomas Kiselak | Director | – | – | Jul 2, 2026 |
| Arlene Morris | Director | – | – | Jul 2, 2026 |
| Christopher W. Cain | Director | – | – | Jul 2, 2026 |
| Funds Management LLC Fairmount | Director, 10% owner | 3,459,913 | 3.05% | May 13, 2026 |
| Healthcare Fund II GP LLC Fairmount | Director, 10% owner | 3,914,458 | 3.46% | May 13, 2026 |
| Healthcare Fund II L.P. Fairmount | Director, 10% owner | 5,090,928 | 4.49% | May 13, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jennifer Tousignant Chief Legal Officer | Aug 19, 2026 | Sale | −4,212 | $24.50 | $103.19K | 0 |
| Jennifer Tousignant Chief Legal Officer | Aug 19, 2026 | Option exercise | +10,000 | $14.41 | $144.10K | 10,000 |
| Jennifer Tousignant Chief Legal Officer | Aug 19, 2026 | Sale | −10,000 | $24.50 | $245.00K | 0 |
| Radhika Tripuraneni Chief Medical Officer | Aug 14, 2026 | Option exercise | +40,000 | $13.21 | $528.40K | 40,000 |
| Healthcare Fund II L.P. Fairmount Director, 10% owner | May 11, 2026 | Buy | +1,176,470 | $17.00 | $20.00M | 5,090,928 |
| Seth Harmon Chief Financial Officer | Mar 3, 2026 | Tax withholding | −2,031 | $30.19 | $61.32K | 7,850 |
| Thomas W. Beetham Chief Operating Officer | Mar 3, 2026 | Tax withholding | −3,048 | $30.19 | $92.02K | 13,361 |
| Jennifer Tousignant Chief Legal Officer | Mar 3, 2026 | Tax withholding | −1,675 | $30.19 | $50.57K | 3,494 |
| Stephen F. Mahoney President and CEO, Director | Mar 3, 2026 | Tax withholding | −7,408 | $30.19 | $223.65K | 33,349 |
| Thomas W. Beetham Chief Operating Officer | Mar 3, 2026 | Tax withholding | −3,138 | $29.32 | $92.01K | 13,271 |
| Thomas W. Beetham Chief Operating Officer | Mar 3, 2026 | Option exercise | +9,409 | – | – | 16,409 |
| Stephen F. Mahoney President and CEO | Mar 3, 2026 | Option exercise | +18,357 | – | – | 40,757 |
| Stephen F. Mahoney President and CEO | Mar 3, 2026 | Tax withholding | −7,627 | $29.32 | $223.62K | 33,130 |
| Seth Harmon Chief Financial Officer | Mar 3, 2026 | Tax withholding | −2,091 | $29.32 | $61.31K | 7,790 |
| Seth Harmon Chief Financial Officer | Mar 3, 2026 | Option exercise | +6,267 | – | – | 9,881 |
| Jennifer Tousignant Chief Legal Officer | Mar 3, 2026 | Tax withholding | −1,724 | $29.32 | $50.55K | 3,445 |
| Jennifer Tousignant Chief Legal Officer | Mar 3, 2026 | Option exercise | +5,169 | – | – | 5,169 |
| Jennifer Tousignant Chief Legal Officer | Dec 31, 2025 | Sale | −2,272 | $31.16 | $70.80K | 0 |
| Healthcare Fund II GP LLC Fairmount Director, 10% owner | Oct 23, 2025 | Buy | +454,545 | $22.00 | $10.00M | 3,914,458 |
| Funds Management LLC Fairmount Director, 10% owner | Jun 10, 2025 | Option exercise | +12,500 | $12.31 | $153.88K | 3,459,913 |
| Funds Management LLC Fairmount Director, 10% owner | Jun 9, 2025 | Option exercise | +1,600 | $7.80 | $12.48K | 3,447,413 |
| Stephen F. Mahoney President and CEO, Director | Sep 27, 2024 | Buy | +21,400 | $23.33 | $499.26K | 21,400 |
| Thomas W. Beetham Chief Operating Officer | Sep 27, 2024 | Buy | +5,000 | $23.41 | $117.05K | 6,000 |
| Healthcare Fund II L.P. Fairmount Director, 10% owner | Sep 13, 2024 | Buy | +1,600,000 | $18.75 | $30.00M | 3,445,813 |
| Healthcare Fund II L.P. Fairmount Director, 10% owner | Mar 28, 2024 | Other | +5,859 | – | – | 1,845,813 |
| Healthcare Fund II L.P. Fairmount Director, 10% owner | Mar 28, 2024 | Other | −5,859 | – | – | 0 |
| Healthcare Fund II L.P. Fairmount Director, 10% owner | Jan 22, 2024 | Buy | +476,190 | $21.00 | $10.00M | 1,839,954 |
| Lara Meisner Chief Legal Officer | Jun 16, 2023 | Option exercise | +27 | $23.03 | $622 | 29,998 |
| Lara Meisner Chief Legal Officer | Jun 16, 2023 | Sale(10b5-1 plan) | −27 | $28.35 | $765 | 29,971 |
| Lara Meisner Chief Legal Officer | Jun 15, 2023 | Option exercise | +2,269 | $23.03 | $52.26K | 32,240 |
| Lara Meisner Chief Legal Officer | Jun 15, 2023 | Sale(10b5-1 plan) | −2,269 | $28.02 | $63.58K | 29,971 |
| Lara Meisner Chief Legal Officer | Jun 6, 2023 | Option exercise | +5,126 | $18.51 | $94.88K | 35,097 |
| Lara Meisner Chief Legal Officer | Jun 6, 2023 | Sale(10b5-1 plan) | −5,126 | $25.02 | $128.25K | 29,971 |
| Lara Meisner Chief Legal Officer | Jun 5, 2023 | Option exercise | +499 | $18.51 | $9.24K | 30,470 |
| Lara Meisner Chief Legal Officer | Jun 5, 2023 | Sale(10b5-1 plan) | −499 | $25.03 | $12.49K | 29,971 |
| Lara Meisner Chief Legal Officer | Jun 2, 2023 | Sale(10b5-1 plan) | −1,875 | $24.21 | $45.39K | 29,971 |
| Lara Meisner Chief Legal Officer | Jun 2, 2023 | Option exercise | +1,875 | $14.00 | $26.25K | 31,846 |
| Scott Dunseth Myers Chief Executive Officer, Director | Apr 12, 2023 | Buy | +4,000 | $25.37 | $101.48K | 259,500 |
| Scott Dunseth Myers Chief Executive Officer, Director | Mar 13, 2023 | Buy | +5,500 | $29.15 | $160.33K | 255,500 |
| Lara Meisner General Counsel and Secretary | Mar 9, 2023 | Sale(10b5-1 plan) | −29,971 | $29.07 | $871.26K | 0 |
| Scott Dunseth Myers Chief Executive Officer, Director | Feb 6, 2023 | Award | +250,000 | – | – | 250,000 |
| Jonathan Violin Chief Executive Officer, Director | Feb 2, 2023 | Option exercise | +50,000 | $0.15 | $7.50K | 530,905 |
| Jonathan Violin Chief Executive Officer, Director | Feb 2, 2023 | Sale(10b5-1 plan) | −50,000 | $36.80 | $1.84M | 480,905 |
| Jonathan Violin Chief Executive Officer, Director | Feb 2, 2023 | Sale(10b5-1 plan) | −50,000 | $36.80 | $1.84M | 430,905 |
| Lara Meisner General Counsel and Secretary | Jan 23, 2023 | Option exercise | +1,872 | $14.00 | $26.21K | 6,843 |
| Lara Meisner General Counsel and Secretary | Jan 23, 2023 | Sale(10b5-1 plan) | −6,843 | $35.66 | $244.02K | 0 |
| Lara Meisner General Counsel and Secretary | Jan 23, 2023 | Option exercise | +4,971 | $23.03 | $114.48K | 4,971 |
| Barrett Katz Chief Medical Officer | Jan 17, 2023 | Sale(10b5-1 plan) | −24,853 | $37.21 | $924.78K | 0 |
| Barrett Katz Chief Medical Officer | Jan 17, 2023 | Option exercise | +24,853 | $23.03 | $572.36K | 24,853 |
| Barrett Katz Chief Medical Officer | Jan 13, 2023 | Sale(10b5-1 plan) | −4,147 | $37.01 | $153.48K | 0 |
| Barrett Katz Chief Medical Officer | Jan 13, 2023 | Option exercise | +4,147 | $23.03 | $95.51K | 4,147 |
| Barrett Katz Chief Medical Officer | Jan 10, 2023 | Sale(10b5-1 plan) | −47,377 | $35.30 | $1.67M | 0 |
| Barrett Katz Chief Medical Officer | Jan 10, 2023 | Option exercise | +47,377 | $23.03 | $1.09M | 47,377 |
| Barrett Katz Chief Medical Officer | Jan 9, 2023 | Sale(10b5-1 plan) | −12,623 | $33.04 | $417.06K | 0 |
| Barrett Katz Chief Medical Officer | Jan 9, 2023 | Option exercise | +12,623 | $23.03 | $290.71K | 12,623 |
| Lara Meisner General Counsel and Secretary | Dec 21, 2022 | Sale(10b5-1 plan) | −16,326 | $29.19 | $476.56K | 0 |
| Lara Meisner General Counsel and Secretary | Dec 21, 2022 | Option exercise | +16,326 | $23.03 | $375.99K | 16,326 |
| Lara Meisner General Counsel and Secretary | Dec 20, 2022 | Sale(10b5-1 plan) | −600 | $28.07 | $16.84K | 0 |
| Lara Meisner General Counsel and Secretary | Dec 20, 2022 | Option exercise | +600 | $23.03 | $13.82K | 600 |
| Lara Meisner General Counsel and Secretary | Dec 16, 2022 | Sale(10b5-1 plan) | −1,297 | $28.44 | $36.89K | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jennifer Tousignant Officer | Aug 19, 2026 | 14,212 | $348.19K | Aug 19, 2026 | Restricted Stock Vesting |
| Thomas W. Beetham Officer | Mar 4, 2026 | 3,048 | $92.00K | Mar 4, 2026 | Restricted Stock Vesting |
| Seth Harmon Officer | Mar 4, 2026 | 2,031 | $61.31K | Mar 4, 2026 | Restricted Stock Vesting |
| Jennifer Tousignant Officer | Mar 4, 2026 | 1,675 | $50.56K | Mar 4, 2026 | Restricted Stock Vesting |
| Stephen F. Mahoney Officer, Director | Mar 4, 2026 | 7,408 | $223.61K | Mar 4, 2026 | Restricted Stock Vesting |
| Jennifer Tousignant Officer | Dec 31, 2025 | 2,272 | $70.80K | Dec 31, 2025 | ESPP Purchase |
| Lara Meisner Former Officer | Dec 18, 2023 | 9,375 | $198.38K | Dec 18, 2023 | Option Granted 02/02/2022 |
| Kristian Humer Former CFO | Dec 12, 2023 | 252,600 | $4.33M | Dec 12, 2023 | Option Granted - 07/26/2021 |
| Kristian Humer Former Officer | Dec 7, 2023 | 24,900 | $470.86K | Dec 7, 2023 | Option Granted - 07/26/2021 |
| Lara Meisner Former Officer | Dec 1, 2023 | 3,125 | $53.03K | Dec 1, 2023 | Option Granted 09/22/2021 |
| Scott Dunseth Myers Former Officer and Director | Nov 16, 2023 | 35,368 | $535.12K | Nov 16, 2023 | Restricted Stock Vesting |
| Lara Meisner Officer | Jun 2, 2023 | 12,469 | $305.49K | Jun 2, 2023 | Stock Option Grant |